|
1
|
Berk BC, Fujiwara K and Lehoux S: ECM
remodeling in hypertensive heart disease. J Clin Invest.
117:568–575. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Opie LH, Commerford PJ, Gersh BJ and
Pfeffer MA: Controversies in ventricular remodelling. Lancet.
367:356–367. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Arribas SM, Hinek A and González MC:
Elastic fibres and vascular structure in hypertension. Pharmacol
Ther. 111:771–791. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Humphrey JD: Mechanisms of arterial
remodeling in hypertension: Coupled roles of wall shear and
intramural stress. Hypertension. 52:195–200. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rossi MA: Pathologic fibrosis and
connective tissue matrix in left ventricular hypertrophy due to
chronic arterial hypertension in humans. J Hypertens. 16:1031–1041.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rossi MA and Peres LC: Effect of captopril
on the prevention and regression of myocardial cell hypertrophy and
interstitial fibrosis in pressure overload cardiac hypertrophy. Am
Heart J. 124:700–709. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rosenkranz S: TGF-beta1 and angiotensin
networking in cardiac remodeling. Cardiovasc Res. 63:423–432. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rizzi E, Castro MM, Ceron CS, Neto-Neves
EM, Prado CM, Rossi MA, Tanus-Santos JE and Gerlach RF: Tempol
inhibits TGF-β and MMPs upregulation and prevents cardiac
hypertensive changes. Int J Cardiol. 165:165–173. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sadoshima J and Izumo S: Molecular
characterization of angiotensin II-induced hypertrophy of cardiac
myocytes and hyperplasia of cardiac fibroblasts. Critical role of
the AT1 receptor subtype. Circ Res. 73:413–423. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao W, Zhao T, Chen Y, Ahokas RA and Sun
Y: Oxidative stress mediates cardiac fibrosis by enhancing
transforming growth factor-beta1 in hypertensive rats. Mol Cell
Biochem. 317:43–50. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bergman MR, Teerlink JR, Mahimkar R, Li L,
Zhu BQ, Nguyen A, Dahi S, Karliner JS and Lovett DH: Cardiac matrix
metalloproteinase-2 expression independently induces marked
ventricular remodeling and systolic dysfunction. Am J Physiol Heart
Circ Physiol. 292:H1847–H1860. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sawicki G, Leon H, Sawicka J,
Sariahmetoglu M, Schulze CJ, Scott PG, Szczesna-Cordary D and
Schulz R: Degradation of myosin light chain in isolated rat hearts
subjected to ischemia-reperfusion injury: A new intracellular
target for matrix metalloproteinase-2. Circulation. 112:544–552.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang W, Schulze CJ, Suarez-Pinzon WL,
Sariahmetoglu M, Schulze CJ, Scott PG, Szczesna-Cordary D and
Schulz R: Intracellular action of matrix metalloproteinase-2
accounts for acute myocardial ischemia and reperfusion injury.
Circulation. 106:1543–1549. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou N, Wang T, Song J, He H, He J and He
L: Antihypertensive and vascular remodelling effects of the
imperatorin derivative OW1 in renovascular hypertension rats. Clin
Exp Pharmacol Physiol. 41:571–578. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Doggrell SA and Brown L: Rat models of
hypertension, cardiac hypertrophy and failure. Cardiovasc Res.
39:89–105. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Committee for the Update of the Guide for
the Care and Use of Laboratory Animals; National Research Council:
Guide for the Care and Use of Laboratory Animals (8th). National
Academies Press. Washington, DC: 2011.
|
|
17
|
Wang C, Wang T, Zhou N, Pan XY and He HZ:
Design, synthesis and evaluation of
9-hydroxy-7H-furo[3,2-g]chromen-7-one derivatives as new potential
vasodilatory agents. J Asian Nat Prod Res. 16:304–311. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gordon D, Mohai LG and Schwartz SM:
Induction of polyploidy in cultures of neonatal rat aortic smooth
muscle cells. Circ Res. 59:633–644. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Marshall NJ, Goodwin CJ and Holt SJ: A
critical assessment of the use of microculture tetrazolium assays
to measure cell growth and function. Growth Regul. 5:69–84.
1995.PubMed/NCBI
|
|
20
|
Maliszewska-Scislo M, Chen H, Augustyniak
RA, Seth D and Rossi NF: Subfornical organ differentially modulates
baroreflex function in normotensive and two-kidney, one-clip
hypertensive rats. Am J Physiol Regul Integr Comp Physiol.
295:R741–R750. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fritz M and Rinaldi G: Influence of nitric
oxide-mediated vasodilation on the blood pressure measured with the
tail-cuff method in the rat. J Biomed Sci. 14:757–765. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ceron CS, Rizzi E, Guimaraes DA,
Martins-Oliveira A, Cau SB, Ramos J, Gerlach RF and Tanus-Santos
JE: Time course involvement of matrix metalloproteinases in the
vascular alterations of renovascular hypertension. Matrix Biol.
31:261–270. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rizzi E, Ceron CS, Guimaraes DA, Prado CM,
Rossi MA, Gerlach RF and Tanus-Santos JE: Temporal changes in
cardiac matrix metalloproteinase activity, oxidative stress, and
TGF-β in renovascular hypertension-induced cardiac hypertrophy. Exp
Mol Pathol. 94:1–9. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schlumberger W, Thie M, Rauterberg J and
Robenek H: Collagen synthesis in cultured aortic smooth muscle
cells. Modulation by collagen lattice culture, transforming growth
factor-beta 1 and epidermal growth factor. Arterioscler Thromb.
11:1660–1666. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang LF, Ding WH, Shi LB, Li K, Haom YJ,
Ke YN and Tang ZS: Effects of exogenous urotensin II on vascular
remodelling after balloon injury. Clin Exp Pharmacol Physiol.
37:477–481. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Browatzki M, Larsen D, Pfeiffer CA, Gehrke
SG, Schmidt J, Kranzhofer A, Katus HA and Kranzhofer R: Angiotensin
II stimulates matrix metalloproteinase secretion in human vascular
smooth muscle cells via nuclear factor-kappaB and activator protein
1 in a redox-sensitive manner. J Vasc Res. 42:415–423. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kranzhöfer R, Schmidt J, Pfeiffer CA, Hagl
S, Libby P and Kübler W: Angiotensin induces inflammatory
activation of human vascular smooth muscle cells. Arterioscler
Thromb Vasc Biol. 19:1623–1629. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
van Leeuwen RT, Kol A, Andreotti F, Kluft
C, Maseri A and Sperti G: Angiotensin II increases plasminogen
activator inhibitor type 1 and tissue-type plasminogen activator
messenger RNA in cultured rat aortic smooth muscle cells.
Circulation. 90:362–368. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Baker KM and Aceto JF: Angiotensin II
stimulation of protein synthesis and cell growth in chick heart
cells. Am J Physiol. 259:H610–H618. 1990.PubMed/NCBI
|
|
30
|
Sorescu D and Griendling KK: Reactive
oxygen species, mitochondria and NAD(P)H oxidases in the
development and progression of heart failure. Congest Heart Fail.
8:132–140. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jel Schultz J, Witt SA, Glascock BJ,
Nieman ML, Reiser PJ, Nix SL, Kimball TR and Doetschman T:
TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by
angiotensin II. J Clin Invest. 109:787–796. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fert-Bober J, Leon H, Sawicka J, Basran
RS, Devon RM, Schulz R and Sawicki G: Inhibiting matrix
metalloproteinase-2 reduces protein release into coronary effluent
from isolated rat hearts during ischemia-reperfusion. Basic Res
Cardiol. 103:431–443. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang GY, Bergman MR, Nguyen AP, Turcato S,
Swigart PM, Rodrigo MC, Simpson PC, Karliner JS, Lovett DH and
Baker AJ: Cardiac transgenic matrix metalloproteinase-2 expression
directly induces impaired contractility. Cardiovasc Res.
69:688–696. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Iwanaga Y, Aoyama T, Kihara Y, Onozawa Y,
Yoneda T and Sasayama S: Excessive activation of matrix
metalloproteinases coincides with left ventricular remodeling
during transition from hypertrophy to heart failure in hypertensive
rats. J Am Coll Cardiol. 39:1384–1391. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Spinale FG: Myocardial matrix remodeling
and the matrix metalloproteinases: Influence on cardiac form and
function. Physiol Rev. 87:1285–1342. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Takenaka H, Kihara Y, Iwanaga Y, Onozawa
Y, Toyokuni S and Kita T: Angiotensin II, oxidative stress and
extracellular matrix degradation during transition to LV failure in
rats with hypertension. J Mol Cell Cardiol. 41:989–997. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Castro MM, Rizzi E, Figueiredo-Lopes L,
Fernandes K, Bendhack LM, Pitol DL, Gerlach RF and Tanus-Santos JE:
Metalloproteinase inhibition ameliorates hypertension and prevents
vascular dysfunction and remodeling in renovascular hypertensive
rats. Atherosclerosis. 198:320–331. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mujumdar VS, Smiley LM and Tyagi SC:
Activation of matrix metalloproteinase dilates and decreases
cardiac tensile strength. Int J Cardiol. 79:277–286. 2001.
View Article : Google Scholar : PubMed/NCBI
|
